4′-phosphate analogs and oligonucleotides comprising the same

Patent metadata

Field	Value
Publication number	US-12037586-B2
Application number	US-202217859781-A
Country	US
Kind code	B2
Filing date	Jul 7, 2022
Priority date	Sep 2, 2016
Publication date	Jul 16, 2024
Grant date	Jul 16, 2024

Abstract

Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4′-phosphate analog and methods of using the same, for example, to modulate the expression of a target gene in a cell. The phosphate analogs are bound to the 4′-carbon of the sugar moiety (e.g., a ribose or deoxyribose or analog thereof) of the 5′-terminal nucleotide of an oligonucleotide. Typically, the phosphate analog is an oxymethylphosphonate, where the oxygen atom of the oxymethyl group is bound to the 4′-carbon of the sugar moiety or analog thereof.

First claim

We Claim:

1. An oligonucleotide comprising a 5′-terminal nucleotide, wherein the 5′-terminal nucleotide is represented by Formula I or II:

wherein R a and R b is each independently selected from hydrogen, CH 3 , CH 2 CH 3 , CH 2 CH 2 CN, CH 2 OCOC(CH 3 ) 3 , CH 2 OCH 2 CH 2 Si(CH 3 ) 3 , or a protecting group;
wherein B is a natural nucleobase, a modified nucleobase, a universal base or absent;
wherein M 1 is O, S, NR′, CR′R″;
wherein R 4 , R 5 , R 6 , or R 7 is each independently selected from hydrogen, halogen, OH, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or wherein two of R 4 , R 5 , R 6 and R 7 are taken together to form a 5-8 membered ring, wherein the ring optionally contains a heteroatom;
wherein X 1 is absent or selected from O, S, NR′, or CR′R″;
wherein Y is an internucleotide linking group attaching the 5′-terminal nucleotide to an oligonucleotide;
wherein R 8 is a glutathione-sensitive moiety or absent;
wherein if R 8 is a glutathione-sensitive moiety, X 2 is O, S, Se, or NR′, or if R 8 is absent, X 2 is H, OH, SH, NH 2 , halogen, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkylthio, optionally substituted alkylamino or dialkylamino wherein one or more methylenes in the alkyl, alkenyl, and alkynyl may be interrupted with one or more of O, S, S(O), SO 2 , N(R′), C(O), N(R′)C(O)O, OC(O)N(R′) optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclic or optionally substituted cycloalkyl, O, S, Se or NHR′; and
wherein R′ and R″ are each independently hydrogen, a halogen, a substituted or unsubstituted aliphatic, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycle or a substituted or unsubstituted cycloalkyl.

2. The oligonucleotide of claim 1 , wherein;
a) the 5′-terminal nucleotide is represented by Formula I;
b) the 5′-terminal nucleotide e is represented by Formula I, wherein X 2 is OH, F, OCH 2 CH 2 OCH 3 , or OCH 3 and R 8 is absent or wherein X 2 is O and R 8 is a glutathione-sensitive moiety;
c) the 5′-terminal nucleotide is represented by Formula I, and R a and R b are hydrogen; R a is CH 3 or CH 2 CH 3 and R b is hydrogen; or R a and R b are each CH 3 or CH 2 CH 3 ; or
d) the 5′-terminal nucleotide is represented by Formula I, wherein X 2 is OH, F, OCH 2 CH 2 OCH 3 , or OCH 3 and R 8 is absent or wherein X 2 is O and R 8 is a glutathione-sensitive moiety, and R a and R b are hydrogen; R a is CH 3 or CH 2 CH 3 and R b is hydrogen; or R a and R b are each CH 3 or CH 2 CH 3 .

3. The oligonucleotide of claim 1 , wherein R a and R b are hydrogen; R a is CH 3 or CH 2 CH 3 and R b is hydrogen; or R a and R b are each CH 3 or CH 2 CH 3 .

4. An oligonucleotide comprising a 5′-terminal nucleotide, wherein the 5′-terminal nucleotide comprises an 4′-oxymethylphosphonate, wherein the 4′-oxymethylphosphonate is —O—CH 2 —PO(OH) 2 or —O—CH 2 —PO(OR) 2 , wherein R is independently selected from H, CH 3 , an alkyl group, or a protecting group.

5. The oligonucleotide according to claim 4 , wherein the alkyl group is CH 2 CH 3 .

6. The oligonucleotide according to claim 1 , wherein the oligonucleotide is a double-stranded RNAi inhibitor molecule comprising a first strand and a second strand, wherein the first strand is a sense strand and the second strand is an antisense strand, and wherein double stranded RNAi inhibitor molecule comprises a region of complementarity between the sense strand and the antisense strand of 15 to 45 nucleotides.

7. The oligonucleotide according to claim 6 , wherein the region of complementarity between the sense strand and the antisense strand is 20 to 30 nucleotides, 21 to 26 nucleotides, 19 to 24 nucleotides, or 19 to 21 nucleotides.

8. The oligonucleotide according to claim 6 , wherein the 5′-terminal nucleotide is located on the antisense strand.

9. The oligonucleotide according to claim 6 , wherein the 5′-terminal nucleotide is located on the sense strand.

10. The oligonucleotide according to claim 6 , wherein the double-stranded RNAi inhibitor molecule contains a tetraloop.

11. The oligonucleotide according to claim 1 , wherein the oligonucleotide is a single stranded oligonucleotide.

12. The oligonucleotide according to claim 11 , wherein the single stranded oligonucleotide is a single stranded RNAi inhibitor molecule.

13. The oligonucleotide according to claim 11 , wherein the single-stranded oligonucleotide is a conventional antisense oligonucleotide, a ribozyme or an aptamer.

14. The oligonucleotide according to claim 12 , wherein the single stranded RNAi inhibitor molecule is 14-50, 16-30, 18-22, or 20-22 nucleotides in length.

15. The oligonucleotide according to claim 1 , wherein the oligonucleotide is a naked oligonucleotide.

16. The oligonucleotide according to claim 1 , further comprising at least one delivery agent, wherein the at least one delivery agent is conjugated to the oligonucleotide to facilitate transport of the oligonucleotide across an outer membrane of a cell.

17. The oligonucleotide according to claim 1 , wherein the delivery agent is selected from the group consisting of carbohydrates, peptides, lipids, vitamins and antibodies.

18. The oligonucleotide according to claim 1 , wherein the delivery agent is selected from N-Acetylgalactosamine (GalNAc), mannose-6-phosphate, galactose, oligosaccharide, polysaccharide, cholesterol, polyethylene glycol, folate, vitamin A, vitamin E, lithocholic acid and a cationic lipid.

19. A pharmaceutical composition comprising the oligonucleotide according to claim 6 and a pharmaceutically acceptable excipient.

20. A method for reducing expression of a target gene in a subject comprising administering the pharmaceutical composition of claim 19 to a subject in need thereof in an amount sufficient to reduce expression of the target gene.

21. The method of claim 20 , wherein the administering comprises systemic administration.

22. A nucleoside phosphoramidite, wherein the nucleoside phosphoramidite is represented by Formula X or Formula XI:

wherein R c and R d is each independently selected from CH 3 , CH 2 CH 3 , CH 2 CH 2 CN, CH 2 OCOC(CH 3 ) 3 , CH 2 OCH 2 CH 2 Si(CH 3 ) 3 , or a protecting group;
wherein B is a natural nucleobase, a modified nucleobase, a universal base or absent;
wherein M 1 is O, S, NR′, CR′R″;
wherein R 4 , R 5 , R 6 , or R 7 is each independently selected from hydrogen, halogen, OH, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or wherein two of R 4 , R 5 , R 6 and R 7 are taken together to form a 5-8 membered ring, wherein the ring optionally contains a heteroatom;
wherein X 10 is absent or selected from O, S, NR′, or CR′R″;
wherein R 10 is a phosphoramidite
wherein R 8 is a glutathione-sensitive moiety or absent;
wherein if R 8 is a glutathione-sensitive moiety, X 2 is O, S, Se, or NR′; or wherein if R 8 is absent, X 2 is H, OH, SH, NH 2 , halogen, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substitute

Assignees

• Dicerna Pharmaceuticals Inc

Inventors

• Wang Weimin
• Li Qingyi
• Nazef Naim

Classifications

• C12N2310/3515

  Lipophilic moiety, e.g. cholesterol · CPC title

• C12N2310/344

  Position-specific modifications, e.g. on every purine, at the 3'-end · CPC title

• C12N2310/322

  2'-R Modification · CPC title

• C12N2310/31

  of the backbone · CPC title

• C12N2310/14

  interfering nucleic acids [NA] · CPC title